<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Ferrario, Carlos M.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">RAAS Inhibitors and the Prevention of Vascular Damage in Patients with Prehypertension</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-10-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">33-34</style></pages><abstract><style  face="normal" font="default" size="100%">Hypertension is a primary mechanism that is responsible for the progression of cardiovascular and renal damage in patients with elevated blood pressure. In particular, functional and structural changes in the vessel wall may represent the key pathological event in the development of hypertension. Within this disease model, prehypertension may be a marker for subclinical vascular disease. This article reviews evidence that supports the treatment of patients with prehypertension.</style></abstract><number><style face="normal" font="default" size="100%">7</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>